Matthew Wisnieff is a litigation associate in the New York office and a member of the Firm's Intellectual Property global practice. Matthew represents domestic and foreign clients in complex commercial litigation, focusing on intellectual property disputes as well as matters concerning the intersection of patent and antitrust law. He regularly represents clients in the pharmaceutical and medical device industries, including Pfizer, Boehringer Ingelheim, and Abiomed. Matthew's practice covers a wide range of matters, including patent disputes, litigation under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act, class action litigation, and advising clients on patent and antitrust law. His practice experience also includes litigation and trial in federal bankruptcy proceedings arising out of the 2008 financial crisis.
Matthew also has extensive experience representing pro bono clients in the area of environmental law. He regularly litigates and advises on Clean Water Act enforcement disputes on behalf of an environmental nonprofit organization. In the past, Matthew has provided legal advice assisting parents of New York City public school students in prevailing in an environmental dispute under the Resource Conservation and Recovery Act.
Represented Pfizer in Hatch-Waxman patent litigation against group of 11 generic drug manufacturers.
Represented Boehringer Ingelheim in antitrust class action/multi-district litigation concerning the settlement of Hatch-Waxman patent litigation between brand and generic pharmaceutical companies.
Represented leading global pharmaceutical company in litigation under the Biologics Price Competition and Innovation Act.
Representation of Abiomed in multiple patent disputes in the medical device industry.
Representation of Pfizer in multiple antitrust class action matters concerning Hatch-Waxman patent litigation settlements between brand and generic pharmaceutical companies.
Representation of Allergan in antitrust class action concerning the settlement of Hatch-Waxman patent litigation between brand and generic pharmaceutical companies.
Pro Bono Award for Outstanding Legal Service, 2019
Pro Bono Award for Outstanding Legal Service, 2016
Pro Bono Award for Outstanding Legal Service, 2013
Pro Bono Award for Outstanding Legal Service, 2012